C-Met-Targeted Antibody Therapy Pipeline Review 2024: Drug Code/INN, Target(S)/Moa, Class Of Compound, Territory Of Main Competitor, Indication(S) & R&D Stage
Date
10/24/2024 10:16:08 AM
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "c-Met-Targeted Antibody Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.
This product provides basic information on antibody therapy candidates in research and development targeting c-Met.
This product consists of:
Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage. Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc). One-month online access to a database for therapeutics and therapy candidates targeting c-Met (prerequisite: access to internet).
The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane receptor tyrosine kinase receptor (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K.
These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types.
In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry. Several c-Met RTK inhibitors have made it to the market to treat non-small cell lung cancer with specific MET mutations - Novartis' Tabrecta (capmatinib), Merk KGaA's Tepmetko (tepotinib) and AstraZeneca and HutchMed's Orpathys (savolitinib) in China - validating c-Met as a viable target. While responses to c-Met RTK inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or exon 14-skipping mutations, representing only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of patients with MET amplification and/or c-Met activation most likely to respond.
As a cell surface receptor, c-Met is highly expressed in solid tumors, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), and, thus, may be well suited as a binding target for delivery of payloads.
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN24102024004107003653ID1108816287
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.